138 related articles for article (PubMed ID: 36028084)
1. Characterization of the physicochemical interactions between exenatide and two intestinal permeation enhancers: Sodium caprate (C
Twarog C; Fattal E; Noiray M; Illel B; Brayden DJ; Taverna M; Hillaireau H
Int J Pharm; 2022 Oct; 626():122131. PubMed ID: 36028084
[TBL] [Abstract][Full Text] [Related]
2. A head-to-head Caco-2 assay comparison of the mechanisms of action of the intestinal permeation enhancers: SNAC and sodium caprate (C
Twarog C; Liu K; O'Brien PJ; Dawson KA; Fattal E; Illel B; Brayden DJ
Eur J Pharm Biopharm; 2020 Jul; 152():95-107. PubMed ID: 32387703
[TBL] [Abstract][Full Text] [Related]
3. Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C
Twarog C; Fattah S; Heade J; Maher S; Fattal E; Brayden DJ
Pharmaceutics; 2019 Feb; 11(2):. PubMed ID: 30781867
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the effects of the intestinal permeation enhancers, SNAC and sodium caprate (C
Twarog C; McCartney F; Harrison SM; Illel B; Fattal E; Brayden DJ
Eur J Pharm Sci; 2021 Mar; 158():105685. PubMed ID: 33359131
[TBL] [Abstract][Full Text] [Related]
5. In Silico-Based Experiments on Mechanistic Interactions between Several Intestinal Permeation Enhancers with a Lipid Bilayer Model.
Kneiszl R; Hossain S; Larsson P
Mol Pharm; 2022 Jan; 19(1):124-137. PubMed ID: 34913341
[TBL] [Abstract][Full Text] [Related]
6. Influence of Bile Composition on Membrane Incorporation of Transient Permeability Enhancers.
Hossain S; Joyce P; Parrow A; Jõemetsa S; Höök F; Larsson P; Bergström CAS
Mol Pharm; 2020 Nov; 17(11):4226-4240. PubMed ID: 32960068
[TBL] [Abstract][Full Text] [Related]
7. Salcaprozate sodium (SNAC) enhances permeability of octreotide across isolated rat and human intestinal epithelial mucosae in Ussing chambers.
Fattah S; Ismaiel M; Murphy B; Rulikowska A; Frias JM; Winter DC; Brayden DJ
Eur J Pharm Sci; 2020 Nov; 154():105509. PubMed ID: 32777258
[TBL] [Abstract][Full Text] [Related]
8. Development and evaluation of C10 and SNAC erodible tablets for gastric delivery of a GIP/GLP1 peptide in monkeys.
Tran H; Dogra M; Huang S; Aihara E; ElSayed M; Aburub A
Int J Pharm; 2024 Jan; 650():123680. PubMed ID: 38070657
[TBL] [Abstract][Full Text] [Related]
9.
Tran H; Aihara E; Mohammed FA; Qu H; Riley A; Su Y; Lai X; Huang S; Aburub A; Chen JJH; Vitale OH; Lao Y; Estwick S; Qi Z; ElSayed MEH
Mol Pharm; 2023 Feb; 20(2):929-941. PubMed ID: 36592951
[TBL] [Abstract][Full Text] [Related]
10. Revealing the interaction between peptide drugs and permeation enhancers in the presence of intestinal bile salts.
Hossain S; Kneiszl R; Larsson P
Nanoscale; 2023 Dec; 15(47):19180-19195. PubMed ID: 37982184
[TBL] [Abstract][Full Text] [Related]
11. Gastrointestinal Permeation Enhancers for the Development of Oral Peptide Pharmaceuticals.
Kim JC; Park EJ; Na DH
Pharmaceuticals (Basel); 2022 Dec; 15(12):. PubMed ID: 36559036
[TBL] [Abstract][Full Text] [Related]
12. Do Macrocyclic Peptide Drugs Interact with Bile Salts under Simulated Gastrointestinal Conditions?
Dening TJ; Douglas JT; Hageman MJ
Mol Pharm; 2021 Aug; 18(8):3086-3098. PubMed ID: 34255531
[TBL] [Abstract][Full Text] [Related]
13. Physical and barrier changes in gastrointestinal mucus induced by the permeation enhancer sodium 8-[(2-hydroxybenzoyl)amino]octanoate (SNAC).
Mortensen JS; Bohr SS; Harloff-Helleberg S; Hatzakis NS; Saaby L; Nielsen HM
J Control Release; 2022 Dec; 352():163-178. PubMed ID: 36314534
[TBL] [Abstract][Full Text] [Related]
14. Impact of Intestinal Concentration and Colloidal Structure on the Permeation-Enhancing Efficiency of Sodium Caprate in the Rat.
Berg S; Kärrberg L; Suljovic D; Seeliger F; Söderberg M; Perez-Alcazar M; Van Zuydam N; Abrahamsson B; Hugerth AM; Davies N; Bergström CAS
Mol Pharm; 2022 Jan; 19(1):200-212. PubMed ID: 34928160
[TBL] [Abstract][Full Text] [Related]
15. Safety concerns over the use of intestinal permeation enhancers: A mini-review.
McCartney F; Gleeson JP; Brayden DJ
Tissue Barriers; 2016; 4(2):e1176822. PubMed ID: 27358756
[TBL] [Abstract][Full Text] [Related]
16. SNAC for Enhanced Oral Bioavailability: An Updated Review.
Kommineni N; Sainaga Jyothi VGS; Butreddy A; Raju S; Shapira T; Khan W; Angsantikul P; Domb AJ
Pharm Res; 2023 Mar; 40(3):633-650. PubMed ID: 36539668
[TBL] [Abstract][Full Text] [Related]
17. Identification of a Multi-Component Formulation for Intestinal Delivery of a GLP-1/Glucagon Co-agonist Peptide.
Tran H; Patel PJ; Aburub A; Sperry A; Estwick S; ElSayed MEH; -Mannan AD
Pharm Res; 2022 Oct; 39(10):2555-2567. PubMed ID: 36050547
[TBL] [Abstract][Full Text] [Related]
18. Design and Development of a New Glucagon-Like Peptide-1 Receptor Agonist to Obtain High Oral Bioavailability.
Chen H; Lu Y; Shi S; Zhang Q; Cao X; Sun L; An D; Zhang X; Kong X; Liu J
Pharm Res; 2022 Aug; 39(8):1891-1906. PubMed ID: 35698011
[TBL] [Abstract][Full Text] [Related]
19. Interaction between Permeation Enhancers and Lipid Bilayers.
Kang C; Bernaldez M; Stamatis SD; Rose JP; Sun R
J Phys Chem B; 2024 Feb; 128(7):1668-1679. PubMed ID: 38232311
[TBL] [Abstract][Full Text] [Related]
20. Sodium caprate enables the blood pressure-lowering effect of Ile-Pro-Pro and Leu-Lys-Pro in spontaneously hypertensive rats by indirectly overcoming PepT1 inhibition.
Gleeson JP; Frías JM; Ryan SM; Brayden DJ
Eur J Pharm Biopharm; 2018 Jul; 128():179-187. PubMed ID: 29684535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
